# **PRODUCT** INFORMATION



C12 Ceramide (d18:1/12:0)

Item No. 22530

CAS Registry No.:	74713-60-3
Formal Name:	N-[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-
	3-heptadecen-1-yl]-dodecanamide
Synonyms:	Cer(d18:1/12:0), C12 Ceramide,
	Ceramide (d18:1/12:0),
	N-Lauroyl-D-erythro-Sphingosine
MF:	C <sub>30</sub> H <sub>59</sub> NO <sub>3</sub>
FW:	481.8 A A A A A A A
Purity:	≥98%
Supplied as:	A solid OH
Storage:	-20°C
Stability:	≥4 years
1 ( )	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

C12 Ceramide (d18:1/12:0) is supplied as a solid. A stock solution may be made by dissolving the C12 ceramide (d18:1/12:0) in the solvent of choice, which should be purged with an inert gas. C12 Ceramide (d18:1/12:0) is soluble in the organic solvent dimethyl formamide at a concentration of approximately 0.50 mg/ml.

## Description

C12 ceramide is a naturally occurring ceramide that is formed when C12 sphingomyelin is hydrolyzed by acid sphingomyelinase (ASM).<sup>1</sup> It is a substrate for acid ceramidase, an enzyme that has 2- to 12-fold higher activity in fibroblasts from patients with Farber disease, a lipid storage disorder.<sup>2</sup> C12 ceramide is found in the Wharton's jelly, a protective coating that surrounds umbilical cord vessels, of babies born to women with pre-eclampsia.<sup>3</sup> BODIPY C12 ceramide has been used to assess levels of ASM activity in plasma of patients with type A or B Niemann-Pick disease.<sup>1</sup>

## References

- 1. He, X., Chen, F., Dagan, A., et al. A fluorescence-based, high-performance liquid chromatographic assay to determine acid sphingomyelinase activity and diagnose types A and B Niemann-Pick disease. Anal. Biochem. 314(1), 116-120 (2003).
- 2. Momoi, T., Ben-Yoseph, Y., and Nadler, H.L. Substrate-specificities of acid and alkaline ceramidases in fibroblasts from patients with Farber disease and controls. Biochem. J. 205(2), 419-425 (1982).
- 3. Romanowicz, L. and Bańkowski, E. Altered sphingolipid composition in Wharton's jelly of pre-eclamptic newborns. Pathobiology 77(2), 78-87 (2010).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/10/2023

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM